Drug Profile

JR 441

Alternative Names: JR-441

Latest Information Update: 07 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator JCR Pharmaceuticals
Class Neuroprotectants; Recombinant fusion proteins
Mechanism of Action Heparan sulfate sulfatase replacements; Transferrin receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Mucopolysaccharidosis III
New Molecular Entity Yes

Highest Development Phases

Phase I/II Mucopolysaccharidosis III

Most Recent Events

25 Dec 2024 JR 441 receives Orphan Drug status for Mucopolysaccharidosis III in Japan
31 Oct 2024 Phase-I clinical trials in Mucopolysaccharidosis III (In infants, In children, In adolescents) in Japan before October 2024 (IV) (jRCT2071240053)
06 Sep 2024 JCR Pharmaceuticals plans a phase I trial for Mucopolysaccharidosis Type IIIA in Japan

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com